Requirement 1: Duration and Consistency of Ranitidine Use
Most Zantac plaintiff's law firms require a minimum of one year of consistent use of Zantac (ranitidine) or generic ranitidine to establish meaningful cumulative NDMA exposure. This threshold reflects the pharmacokinetic and epidemiological evidence showing that cancer risk from NDMA is a function of sustained, repeated exposure over time — not acute or occasional use. Both prescription ranitidine and over-the-counter Zantac qualify. Use does not need to have been daily or uninterrupted; patients who used ranitidine several times per week for chronic heartburn or GERD management over a multi-year period can satisfy the use requirement. The important factors are the total duration of the use period and the frequency of use within that period. Use prior to the April 2020 FDA withdrawal is most relevant, as that is when ranitidine products were available for purchase. Evidence of use includes pharmacy prescription records, insurance claims data, store loyalty card purchase histories, and corroborating physician records documenting ranitidine prescriptions or OTC use discussions.
Requirement 2: Qualifying Cancer Diagnosis
You must have been diagnosed with a cancer type that is accepted in active Zantac state court litigation. The most widely accepted qualifying cancers are: bladder cancer (urothelial carcinoma), stomach (gastric) cancer, colorectal cancer (colon and rectal), and esophageal cancer. Breast cancer and prostate cancer are also pursued as qualifying diagnoses by many plaintiff's firms. The cancer diagnosis must be confirmed by pathology report. Any stage qualifies, though earlier-stage diagnoses result in lower settlement values than advanced-stage or metastatic disease. A cancer diagnosis that predates any significant period of ranitidine use (i.e., you had cancer before you started taking Zantac) would not qualify.
Requirement 3: Medically Plausible Exposure-to-Diagnosis Timeline
There must be a medically plausible latency period between the period of ranitidine use and the cancer diagnosis. Cancer induced by chemical carcinogens such as NDMA typically develops over years to decades — short-term exposure immediately before diagnosis would not support a causal theory. Claimants who used ranitidine for several years and were diagnosed with a qualifying cancer several years or more after beginning use present the strongest timeline. For example, a patient who used ranitidine from 2005 to 2018 and was diagnosed with bladder cancer in 2021 has a compelling timeline — the diagnosis follows years of cumulative NDMA exposure with adequate latency. Conversely, a patient who began using ranitidine in January 2020 and was diagnosed with cancer in June 2020 would face serious timeline challenges.
Requirement 4: Filing Within the Statute of Limitations
Your claim must be timely under the applicable state statute of limitations. In pharmaceutical cases, the discovery rule typically governs — the clock begins when you knew or should have known that Zantac may have caused your cancer. The April 2020 FDA market withdrawal is often cited as the date when public notice of the NDMA-ranitidine connection became widely available, meaning that in many states the limitations period began running in April 2020. Claimants diagnosed with qualifying cancers in 2022 or later, or those who can demonstrate delayed discovery of the Zantac connection, may still have timely claims in 2026. A pharmaceutical litigation attorney can evaluate the specific limitations period applicable to your diagnosis date and state.
Frequently Asked Questions
Related Pages
Zantac NDMA Contamination Explained
NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
The Valisure Study — How the NDMA Problem Was Discovered
Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac Federal MDL Dismissal — What Happened
The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
Zantac State Court Litigation — Delaware and California 2026
Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
Zantac Brand vs. Generic — All Manufacturers Are Liable
The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview